Hematopoietic growth factor combination

This page covers all Hematopoietic growth factor combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting G-CSF receptor; GM-CSF receptor, G-CSF receptor (GCSFR) and Erythropoietin receptor (EPOR).

Targets

G-CSF receptor; GM-CSF receptor · G-CSF receptor (GCSFR) and Erythropoietin receptor (EPOR)

Marketed (1)

• rhG-CSF+rhGM-CSF group · Xiamen Amoytop Biotech Co., Ltd. · Oncology; Hematology
  This combination of recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) stimulates the production and activation of neutrophils and myeloid cells to enhance immune function and hematopoietic recovery.

Phase 3 pipeline (1)

• G-CSF+EPO · Institute of Liver and Biliary Sciences, India · Hematology / Hepatology
  G-CSF stimulates neutrophil production while EPO stimulates red blood cell production, together enhancing hematopoietic recovery and tissue oxygenation.

Patent intelligence

• hematopoietic growth factor combination patent landscape — aggregated cliff calendar, attackable patents, originator estates